Treatment of Postmenopausal Osteoporosis: An Evidence-Based Approach

Reviews in Endocrine and Metabolic Disorders

Volumn 2, Issue 1, 2001, Pages 35-43

  Rosen, Clifford J ^a,b  

^a ST JOSEPH HOSPITAL   (United States)

^b JACKSON LABORATORY   (United States)

Author keywords

Evidence; Hisphosphonates; Osteoporosis; Prevention

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN;

AGED; ESTROGEN THERAPY; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; MIDDLE AGED; POSTMENOPAUSE OSTEOPOROSIS; REVIEW;

AGED; CALCITONIN; DIPHOSPHONATES; ESTROGEN REPLACEMENT THERAPY; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 0035232561     PISSN: 13899155     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1010002907247     Document Type: Article

References (53)

1. Melton LJ. How many women have osteoporosis now. J Bone Miner Res 1995;10:175-177.
2. Cooper C, Atkinson EJ, Jacobsen SJ, O'Fallon WM, Melton LJd. Population based study of survival after osteoporotic fracture. Am J Epidemiol 1993;137:1001-1005.
3. Nevitt MC, Ettinger B, Black DM, Stone K, Jamal SA, Ensrud K, Segal M, Genant HK, Cummings SR. The association of radiographically detected vertebral fractures with back pain and function: A prospective study. Ann Int Med 1998;128:793-800.
4. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994;309:1286-1291.
5. Cook DJ, Sackett DJl, Spitzer WO. Methodologie guidelines for systematic reviews of randomized control trials in health care from the Potsdam consultation on meta analysis. J Clin Epidemiol 1995;481:67-71.
6. Fleisch HA. Bisphosphonates: Preclinical aspects and use in osteoporosis. Ann Med 1997;29:55-62.
7. Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, Cauley J, Black D, Vogt TM. Risk factors for hip fracture in white women. N Engl J Med 1995;332:767-773.
8. Karpf DB, Shapiro DR, Seeman E, Ensrud KE, Johnston CC, Jr., Adami S, Harris ST, Santora AC, 2nd, Hirsch LJ, Oppenheimer L, Thompson D. Prevention of non-vertebral fractures by alendronate. A meta analysis. JAMA 1997;277:1159-1164.
9. Marshall D, Johnell O, Wedel H. Meta analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254-1359.
10. Black DM, Pearson J, Harris F, LaCroix A, Cummings SR. Predicting the effect of antiresorptive treatments on risk of vertebral fractures: A meta analysis. J Bone Miner Res 1999;14:s1:1017.
11. Riggs BL, Hodgson SF, O'Fallon WM, Chao EY, Whaner HW, Muhs JM, Cedel SL, Melton LJ. Effect of fluoride treatment of the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990;323:416-419.
12. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin d supplementation on bone density in men and women 65 years of age and older. N Engl J Med 1997;337:670-676.
13. Albright F. Postmenopausal osteoporosis. JAMA 1941;116:2465-2474.
14. Manolagas SC, Jilka RL. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995;332:305-311.
15. Jilka RG, Girsole GH, Passeri G, Williams D, Abrams J, Boyce B, Broxmeyer H, Manoloagas S. Increased osteoclast development after estrogen loss: Mediation by il-6. Science 1992;257: 88-91.
16. Pacifici R, Brown C, Puscheck E. The effect of surgical menopause and estrogen replacement on cytokine release from human blood monocytes. Proc Natl Acad Sci USA 1991;88:5134-5138.
17. Rosen CJ, Chesnut CH, Mallinak NJ. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement and calcium supplementation. J Clin Endocrinol Metab 1997;82:1904-1910.
18. The writing group for PEPI. Effects of hormone therapy on bone mineral density. JAMA 1996;17:1389-1496.
19. Lindsay R, Hart DM, Aitken JM, MacDonald EB, Anderson JB, Clarke AC. Long term prevention of postmenopausal osteoporosis by estrogen. Evidence for an increased bone mass after delayed onset of estrogen treatment. Lancet 1976;1:1038-1041.
20. Lindsay R, Tohme JF. Estrogen treatment of patients with established postmenopausal osteoporosis. Obstet Gynecol 1990;76:290-295.
21. Ettinger B, Genant HK, Steiger P, Madvig P. Low dosage micronized 17 beta estradiol prevents bone loss in postmenopausal women. Am J Obstet Gynecol 1992;166:479-488.
22. Nieves JW, Komar L, Cosman F, Lindsay R. Calcium potentiates the effect of estrogen and calcitonin on bone mass. Review and analysis. Am J Clin Nutr 1998;67:18-24.
23. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. Estrogen replacement therapy and fractures in older women. Ann Int Med 1995;122:9-16.
24. Hulley S, Grady D, Bush T. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-613.
25. Lufkin EG, Wahner HW, O'Fallon WM, Hodgson SF, Kotowitz MA, Lane AW. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Int Med 1992;44:131-136.
26. Love RR, Mazess RB, Barden HS, Espstein S, Newcomb PA, Jordan VC, Carbone PP, DeMets DL. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852-856.
27. Fisher B, Constantino JP, Wikderham DL. Tamoxifen for prevention of breast cancer. J Natl Cancer Inst 1998;90:1371-1388.
28. Goldstein SR. Selective estrogen receptor modulators: A new category of therapeutic agents for extending the health of postmenopausal women. Am J Obstet Gynecol 1998;179:1479-1488.
29. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-1747.
30. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C. A controlled trial of raloxifene HCL: Impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 1996;11:835-942.
31. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christianson C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA 1999;282:637-645.
32. Lufkin EG, Whitaker MD, Nickelesen T, Argueta R, Caplan RH, Knickerbocker RK, Riggs BL. Treatment of established post-menopausal osteoporosis with raloxifene; a randomized trial. J Bone Miner Res 1998;13:1747-1754.
33. Cardona JM, Pastor E. Calcitonin versus etidronate for the treatment of postmenopausal osteoporosis: A meta analysis of published trials. Osteoporosis Int 1997;7:165-174.
34. Silverman SL, Chesnut C, Andriano K, Genant H, Gimona A, Maricic M, Stock J, Baylink D. Salmon calcitonin nasal spray reduces risk of vertebral fractures in established osteoporosis and has continuous efficacy with prolonged treatment: Accrued 5 year worldwide data of proof. Bone 1998;23:5S1;174.
35. Rodan GA, Seedor JG, Balena R. Preclinical pharmacology of alendronate. Osteoporosis Int 1993;S712.
36. Miller PD, Watts NB, Licata AA, Harris ST, Genant HK, Wasnich RD, Ross PD, Jackson RD, Hoseyni MS, Schoenfeld SL, Valent DJ, Chesnut CH, 3rd. Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment. Am J Med 1997;103:468-476.
37. Ryan PJ, Fogelman I. Clinical experience with etidronate in osteoporosis. Clin Rheum 1994; 13:455-458.
38. Storm T, Thamsborg G, Steiniche T, Genant HK, Sorenson OH. Effect of intermittent cyclic etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990;322:1265-1271.
39. Meunier PJ, Confavreux E, Tupinon I, Hardouin C, Delmas PD, Balena R. Prevention of early postmenopausal boen loss with cyclical etidronate therapy. J Clin Endocrinol Metab 1997;82:84-91.
40. Ott Sm, Woodson GC, Huffer WE, Miller PD, Watts NB. Bone histomorphometric changes after cyclic therapy with phosphate and etidronate disodium in women with pmo. J Clin Endocrinol Metab 1994;78:968-1072.
41. Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GCd, Yanover MJ. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990;323:73-79.
42. Harris ST, Watts NB, Jackson RD, Genant HK, Wasnich RD, Ross P, Miller PD, Licata AA, Chesnut CHd. Four year study of intermittent cyclic etidronate treatment of PMO: Three years of blinded therapy followed by one year open therapy. Am J Med 1993;95:557-567.
43. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE. Randomized trial of the effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Loancet 1996;348:1535-1541.
44. Cummings ST, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. Results from the fit. JAMA 1998;280:2077-2082.
45. Hosking D, Chilvers CE, Christiansen C, Ravn P, Wasnich R, Ross P, McClung M, Balske A, Thompson D, Daley M, Yates AJ. Prevention of bone loss with alendronate in postmneopausal women under 60 years of age. N Engl J Med 1998;338:485-492.
46. Lieberman UA, Weiss SR, Broll et al. Effect on oral alendronate on bone mineral density and the incidence of fractures in post-menopausal osteoporosis. The alendronate phase iii osteoporosis treatment study group. N Engl J Med 1995;333:1437-1443.
47. Chesnut CH, McClung MR, Ensrud KE, Bell NH, Genant HK, Harris ST, Singer FR, Stock JL, Yood RA, Delmas PD. Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling. Am J Med 1995;99:144-152.
48. Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB. Early changes in biochemical markers of bone turnover predict the long term repsonse to alendronate in representative elderly women: A randomized clinical trial. J Bone Miner Res 1998;13:1431-1438.
49. Tucci JR, Tonino RP, Emkey RD, Peverly CA, Kher U, Santora AC, 2nd. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 1996;101:488-501.
50. Watts N, Freedholm D, Daifotis A. The clinical tolerability profile of alendronate. Int J Clin Pharm S1 1999;51-61.
51. Mosekilde L, Mosekilde L, Davidson CC. Biomechanical competence of vertebral trabecular bone in relation to ash density and age in normal individuals. Bone 1987;79-82.
52. Melton W, Khosla S, Atkinson EJ, O Fallon WM, Riggs BL. Relationship of bone turnover to bone density and fractures. J Bone Miner Res 1997;12:1083-1091.
53. Watts N, Roux C, Genant H, Adami S, Hangartner T, Miller P, Sorensen O, Hooper M, Ethgen D, Valent D. Risedronate reduces vertebral fracture risk after the first year of treatment in postmenopausal women with established osteoporosis. J Bone Miner Res 1016.